Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Progenics Pharmaceuticals Inc. PGNX

Healthcare Biotechnology
"Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate... see more

Recent & Breaking News (NDAQ:PGNX)

Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

GlobeNewswire June 2, 2016

Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results

GlobeNewswire May 5, 2016

Adesto Technologies Announces First Quarter Financial Results

GlobeNewswire May 5, 2016

Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies

GlobeNewswire May 2, 2016

Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5

GlobeNewswire April 21, 2016

Market Exclusive Research Weekly Biotech Report

Accesswire April 18, 2016

Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference

GlobeNewswire April 6, 2016

Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR

Canada NewsWire April 4, 2016

Biotech Sector Report Analyst; Expecting FDA Results

Accesswire March 28, 2016

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results

GlobeNewswire March 11, 2016

Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference

GlobeNewswire March 9, 2016

Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2015 Financial Results Call for March 11

GlobeNewswire March 1, 2016

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report

Accesswire February 9, 2016

Progenics Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire February 1, 2016

Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer

GlobeNewswire January 7, 2016

Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra(TM)

GlobeNewswire December 3, 2015

Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer

GlobeNewswire November 16, 2015

Progenics Pharmaceuticals to Present at the Stifel Healthcare Conference

GlobeNewswire November 10, 2015

Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results

GlobeNewswire November 9, 2015

Progenics Pharmaceuticals Sets Third Quarter Financial Results Call for November 9

GlobeNewswire November 2, 2015